8 Penny Stocks in Focus: What's Behind the Plunge in China SXT, Sunshine Biopharma, and Medicus Pharma

Key Highlights

• China SXT Pharmaceuticals, Inc. fell nearly 89% after pricing a USD 12 million share offering
• Sunshine Biopharma, Inc. dropped about 40% following a USD 6 million public offering
• Medicus Pharma Ltd. fell nearly 38% despite a shareholder update on its oncology pipeline
• Five other penny stocks moved on contract, trial, and regulatory news, with more modest swings
• New share issuance, not business setbacks, drove today's steepest declines

Penny stocks, generally defined as shares trading under USD 5, tend to see far sharper price swings than their larger peers, and today was a clear example. Three names, China SXT Pharmaceuticals, Inc., Sunshine Biopharma, Inc., and Medicus Pharma Ltd., accounted for the steepest declines among eight penny stocks in motion today. A closer look shows a common thread behind two of the three moves, while the third points to a different kind of investor concern.

The Common Thread: New Share Offerings Drive the Biggest Drops

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC), a Chinese company focused on traditional Chinese medicine products, fell nearly 89% after entering a definitive agreement to sell 8 million shares at USD 1.50 per share in a registered direct offering, alongside matching warrants. Expected gross proceeds are about USD 12 million. The scale of the offering relative to the company's small size likely explains the severity of the drop, since new shares entering the market dilute the value of existing holdings.

Sunshine Biopharma, Inc. (NASDAQ:SBFM), a Florida-based pharmaceutical company developing oncology and antiviral treatments, saw shares fall about 40% after pricing a public offering of roughly 10.9 million units at USD 0.55 per unit, expected to raise about USD 6 million before fees. As with China SXT, the size of the raise relative to the company's market value appears to have driven the reaction more than any change in its underlying business.

Both cases follow a familiar pattern in small-cap biotech. A company facing cash constraints turns to the public markets for fresh capital, and the resulting increase in share count can outweigh any positive signal that the company has secured funding to continue its operations.

A Shareholder Update That Didn't Reassure the Market

Medicus Pharma Ltd. (NASDAQ:MDCX), a Canadian-led, precision oncology-focused biotech, fell nearly 38% even as it marked its third year as a public company with a shareholder update on its three lead programs: an antibody-drug conjugate for solid tumors, a skin cancer treatment for a rare genetic condition now advancing toward a registrational study, and a hormone therapy for prostate cancer. Unlike China SXT or Sunshine Biopharma, this decline was not tied to a new offering. The drop instead suggests the market may have focused more on the company's continued reliance on outside capital and its still-early pipeline than on the progress outlined in the update itself.

Smaller Moves on Contracts, Filings, and Trials

Not every penny stock move today was linked to financing concerns. Five other names saw more modest swings tied to operational or clinical news.

Co-Diagnostics, Inc. (NASDAQ:CODX) slipped slightly despite announcing its first full mosquito-surveillance laboratory installation for a Native American tribal health department. Daré Bioscience, Inc. (NASDAQ:DARE) also edged lower after presenting Phase 1 data showing lower systemic drug exposure for a topical cream being developed for a female sexual health condition. Biofrontera Inc. (NASDAQ:BFRI) dipped after filing with the FDA to expand use of its approved skin treatment to cover more of the body, backed by Phase 3 data showing meaningfully higher lesion clearance than placebo. Nexalin Technology, Inc. (NASDAQ:NXL) fell despite confirming it regained compliance with a Nasdaq listing requirement, though a separate equity threshold still looms in January 2027. Aclarion, Inc. (NASDAQ:ACON) slipped modestly after widening enrollment criteria for its ongoing back pain diagnostic trial to address lagging patient recruitment.

Why Penny Stocks React This Way

The pattern across today's steepest declines points to a familiar dynamic in small, thinly capitalized companies. A share offering that would barely register for a larger company can represent a significant percentage of a penny stock's existing share count, which may explain why dilution-driven selloffs were sharper than reactions to clinical or regulatory news. Trading volume across several of today's biggest movers also surged well above typical levels, a sign that the moves drew outsized attention relative to each company's usual trading activity.

The Bottom Line

Today's penny stock activity shows that financing decisions, not business fundamentals, drove the sharpest declines, while clinical and regulatory updates produced far more muted reactions either way. For readers following this corner of the market, the gap between China SXT and Sunshine Biopharma's dilution-driven plunges and Medicus Pharma's more sentiment-driven decline is a reminder that penny stocks can swing sharply for very different reasons, and that a steep drop alone does not always point to the same underlying cause.